EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In Vitro Killing of Gram-Negative Bacilli Using Ciprofloxacin Based on Dry Powder Inhaled Drug Concentrations

Joseph M. Blondeau, Shantelle D. Fitch

Pharmaceutics · 11.11.2026 · 18 (11) · 1460

DOI: 10.3390/pharmaceutics18111460 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 11.11.2026. Verfasst von Joseph M. Blondeau und 1 weiteren Autor:innen. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bayer Pharma, Royal University Hospital Foundation.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Inhaled drug formulations are reported to deliver high airway pulmonary drug concentrations with minimal systemic adverse effects. High drug concentrations with fluoroquinolones are desirable as they are concentration-dependent antibacterial agents.

Methods

We exposed drug-susceptible strains of Escherichia coli, Enterobacter cloacae, Klebsiella pneumoniae and Pseudomonas aeruginosa to the measured minimum inhibitory and mutant prevention drug concentrations and to the mean reported pulmonary drug concentrations of ciprofloxacin in vitro by incubation in 3 h and 24 h kill assays.

Results

Using 105 cfu/mL in the 3 h kill assay, ciprofloxacin at a 409 µg/mL pulmonary drug concentration killed 89.6 (1.4 log10)–99.9% (4.4 log10) of cells across all tested species following 5 min of drug exposure. For 106–109 cfu/mL in the 24 h kill assay, ciprofloxacin at 409 µg/mL killed 93.6 (1.3 log10)–99.7% (2.7 log10) of P. aeruginosa cells following 6 h of drug exposure across all bacterial densities; 97.4 (1.3 log10)–100% (6.4 log10) of E. coli, 99.4 (2.9 log10)–99.9% (5.9 log10) of E. cloacae and 98.7 (2.1 log10)–100% (7.5 log10) of K. pneumoniae following 24 h of drug exposure.

Conclusions

The ciprofloxacin pulmonary drug concentration was bactericidal over all bacterial densities with the high drug concentration rapidly reducing viable bacterial cells. Clinical correlation of these in vitro observations is warranted. Additionally, in vitro testing using the drug powder formation may further validate these observations.

Förderung

  • Bayer Pharma
  • Royal University Hospital Foundation

Zitieren

APA

Blondeau, J. M., & Fitch, S. D. (2026). In Vitro Killing of Gram-Negative Bacilli Using Ciprofloxacin Based on Dry Powder Inhaled Drug Concentrations. Pharmaceutics, 18(11), 1460. https://doi.org/10.3390/pharmaceutics18111460

Vancouver

Blondeau JM, Fitch SD. In Vitro Killing of Gram-Negative Bacilli Using Ciprofloxacin Based on Dry Powder Inhaled Drug Concentrations. Pharmaceutics. 2026;18(11):1460. doi:10.3390/pharmaceutics18111460

BibTeX
@article{Blondeau2026,
  author = {Blondeau, Joseph M. and Fitch, Shantelle D.},
  title = {In Vitro Killing of Gram-Negative Bacilli Using Ciprofloxacin Based on Dry Powder Inhaled Drug Concentrations},
  journal = {Pharmaceutics},
  year = {2026},
  volume = {18},
  number = {11},
  pages = {1460},
  doi = {10.3390/pharmaceutics18111460}
}
Kostenlos starten →